ÖZ Amaç Çalışmada skorlama sistemlerinin koronavirüs hastalığı-2019 (COVİD-19) şiddetini belirleyip belirlemediğini araştırdık. Gereç ve Yöntem 01.09.2020 ve 31.04.2021 tarihleri arasında yatan COVİD-19 hastaları retrospektif olarak incelendi. Başvuru günündeki ulusal erken uyarı skoru (NEWS), modifiye erken uyarı skoru, hızlı acil tıp skoru, tekrarlanan-sepsis ilişkili organ yetmezliği hızlı değerlendirmesi skoru (q-SOFA), CURB-65, MuLBSTA ve ISARIC 4C skorları hesaplandı. Skorlama sistemlerinin mekanik ventilasyon (MV) ihtiyacını, yoğun bakım ünitesine (YBÜ) yatışını ve 30 günlük mortaliteyi öngörme kapasitesi incelendi. Bulgular Toplam 292 hasta dahil edildi, 137’si (%46,9) kadındı, yaş ortalaması 62,5±15,4 yıldı. Hastaların 69’unun (%23,6) YBÜ yatışı gerekti, 45 (%15,4) hastada MV’ye ihtiyaç duyuldu ve 49 (%16,8) hasta 30 gün içinde öldü. Q-SOFA ile MV ihtiyacı arasında bir ilişki bulunmadı (p=0,167) ancak diğer tüm skorlama sistemleri ile MV ihtiyacı, YBÜ yatış ve 30 günlük mortalite arasında istatistiksel olarak anlamlı bir ilişki bulundu (p5,5) ve NEWS (optimal cut-off >3,5) iken en düşük q-SOFA idi. Sonuç İlk başvurularında ISARIC-4C ve NEWS başta olmak üzere mevcut skorlama sistemleri kullanılarak COVİD-19’un şiddeti tahmin edilebilecektir. Böylece gerekli müdahalelerin daha erken yapılarak mortalite ve morbiditenin azaltılabilecektir.
Objective: Toxoplasmosis is a parasitosis that is mostly asymptomatic. It can lead to severe clinical conditions in immunosuppressed patients and fetal infections. Since it is possible to prevent congenital toxoplasmosis with appropriate follow-up and treatment, our study aimed to determine the susceptible population and seroprevalence of our region and to evaluate the course of infections in this group. Material and Method: Patients who applied to our tertiary hospital in the last five years and to whose Anti Toxoplasma IgM and IgG tests were performed were included in our study. Toxoplasmosis seroprevalence, the course of primary infection in pregnant women, the treatments applied, and also acute toxoplasmosis infections in non-pregnant patients were examined. Results: The seropositivity rate was found to be 30.7% (n=1703) in 5545 women included in the study, and the seropositivity rate was 31% (n=1399) in 4503 pregnant women. Sixteen pregnant women with primary infection were followed up in our hospital; one underwent medical abortion at the request of the family, and only four used the recommended treatment. Congenital toxoplasmosis was not detected in any newborn. Of the patients included, 26 (0.4%) were examined to investigate the etiology of fever, 37 (0.6%) for lymphadenopathy (LAP), and 29 (0.5%) for elevated liver enzymes. Among the patients with LAP, four (10.8%) were diagnosed with acute toxoplasmosis. Conclusion: As a result, it is important to determine the seroprevalence of toxoplasmosis, to detect possible primary infections, especially in pregnant women, and ensure close monitoring of these patients.
The pathogenesis of COVID-19 highlights a complex relationship between disease severity and neutralizing antibodies (NAbs). We aimed to investigate the relationships among the total NAb (tNAb) levels, the presence of potential neutralization antibodies (pNAbs), and the clinical outcomes of COVID-19 patients. Patients aged ≥18 years diagnosed between October 2021 and September 2022 were grouped by symptom severity. Blood samples were taken at two time points and data on demographics, epidemiology, and vaccination were recorded. The tNAbs and pNAbs were measured by an enhanced chemiluminescence assay and a surrogate virus neutralization test, respectively. The tNAbs of 68 and the pNAbs of 52 patients were analyzed. Twenty-six (38.2%) patients had severe infection. The 28-day mortality rate was 16.2% (n = 11). The tNAb levels in the control blood samples (CBSs) were significantly higher than those of the admission blood samples (ABSs) (p < 0.001). The statistical analysis showed no relationship between disease severity and pNAbs. Vaccinated patients had significantly higher tNAbs in the ABSs and CBSs (p < 0.001 and p < 0.001, respectively). The presence of pNAbs in the ABSs was correlated with a lower 28-day mortality (p = 0.026) and a milder disease course (p = 0.041). Although these findings support a correlation between tNAbs and disease severity and mortality, their presence seems to be unrelated to favorable clinical outcomes.
22 September 2023 in Flora the Journal of Infectious Diseases and Clinical Microbiology
To quantify the prevalence of HIV testing indications among hospitalised adults in Türkiye, assess HIV testing coverage when clinically indicated, and identify missed diagnostic opportunities in a national multicentre point-prevalence survey. We conducted a national multicentre cross-sectional point-prevalence survey across tertiary referral hospitals from all seven geographical regions of Türkiye. Adult inpatients present at 08:00 on a predefined index day were assessed for predefined HIV testing indications, including AIDS-defining conditions, indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and conditions in which unrecognised HIV could substantially affect clinical management. Among 3,425 hospitalised adults without known HIV infection, 699 (20.4%) had at least one documented HIV testing indication. HIV testing was requested by the primary clinical team in 424/699 patients (60.7%). Testing was lowest in patients with indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and these conditions were independently associated with higher odds of non-performance of HIV testing by the primary clinical team than AIDS-defining conditions (corresponding adjusted odds ratio [aOR] 3.05, 95% confidence interval [CI] 1.67–5.81). In centres with a specialised HIV outpatient clinic, the odds of non-performance of HIV testing by the primary clinical team were independently lower among patients with an appropriate testing indication (corresponding aOR 0.64, 95% CI 0.43–0.95). Following study-team facilitation, overall testing coverage increased to 677/699 (96.9%). Three reactive screening results were identified, including two confirmed new HIV diagnoses. HIV testing indications were common among hospitalised adults in Türkiye, but non-performance of HIV testing by the primary clinical team remained frequent, particularly for non-AIDS indicator conditions. Strengthening indicator-condition-guided testing through structured clinical pathways and institutional HIV expertise may reduce non-performance and support earlier HIV diagnosis.